Balancing immunity and pathology in visceral leishmaniasis

Immunology and Cell Biology - Tập 85 Số 2 - Trang 138-147 - 2007
Amanda C. Stanley1, Christian Engwerda1
1Immunology and Infection Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia.

Tóm tắt

Experimental visceral leishmaniasis (VL) caused by infection with Leishmania donovani results in the development of organ‐specific immunity in the two main target tissues of infection, the spleen and the liver. The liver is the site of an acute resolving infection associated with the development of inflammatory granulomas around infected Kupffer cells, and resistance to reinfection. Paradoxically, the spleen is an initial site for the generation of cell‐mediated immune responses, but ultimately becomes a site of parasite persistence with associated immunopathological changes. These include splenomegaly and a breakdown in tissue architecture that is postulated to contribute to the immunocompromized status of the host. The progressive development of splenic pathology is largely associated with high levels of TNF and interleukin (IL)‐10. Follicular dendritic cell (DC) networks are lost, whereas TNF mediates the destruction of marginal zone macrophages and gp38+ stromal cells, and IL‐10 promotes impaired DC migration into T‐cell areas with consequent ineffective T‐cell priming. Splenic stromal cell function is also altered, promoting the selective development of IL‐10‐producing DC with immunoregulatory properties. Ultimately, a fine immunological balance determines responses that effectively promote parasite clearance in the liver and those that promote pathology in the spleen, and future investigation aims to separate these responses to offer further means of parasite control in chronically infected VL patients.

Từ khóa


Tài liệu tham khảo

UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Leishmaniasis: Disease Information

Gardener PJ, 1977, Taxonomy of the genus Leishmania: a review of nomenclature and classification, Trop Dis Bull, 74, 1069

10.4269/ajtmh.1989.41.687

Wilson ME, 1996, Local suppression of IFN‐gamma in hepatic granulomas correlates with tissue‐specific replication of Leishmania chagasi, J Immunol, 156, 2231, 10.4049/jimmunol.156.6.2231

Smelt SC, 1997, Destruction of follicular dendritic cells during chronic visceral leishmaniasis, J Immunol, 158, 3813, 10.4049/jimmunol.158.8.3813

10.1136/bmj.312.7025.247

10.1016/S0035-9203(01)90218-4

Dedet JP, 2003, Leishmaniasis

10.1136/bmj.326.7385.377

Baker R, 1999, The Granulomatous Diseases, 212

10.1128/CMR.19.1.111-126.2006

10.1016/S1473-3099(03)00517-6

10.1046/j.1365-2249.1998.00468.x

Ali A, 2002, Leishmaniases and HIV/AIDS co‐infections: review of common features and management experiences, Ethiop Med J, 40, 37

10.1097/00001432-200210000-00005

10.1086/344325

10.1046/j.1365-4362.2002.01610.x

10.1128/JCM.40.3.762-767.2002

10.1128/IAI.71.1.401-410.2003

10.1046/j.1462-5822.2001.00150.x

10.1084/jem.185.4.717

Leclercq V, 1996, The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue‐dependent pattern controlled by the Lsh and MHC loci, J Immunol, 157, 4537, 10.4049/jimmunol.157.10.4537

10.1128/IAI.43.3.1033-1040.1984

10.1016/0923-2494(89)90036-9

10.1189/jlb.0904546

10.1016/0923-2494(89)90029-1

10.1084/jem.182.3.655

10.1007/BF00368537

10.1038/sj.ejhg.5201089

10.1128/IAI.71.4.2095-2101.2003

10.1128/IAI.70.9.5026-5035.2002

10.4049/jimmunol.170.5.2613

10.1128/IAI.70.12.6828-6838.2002

10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N

10.1128/IAI.60.10.4335-4342.1992

10.1128/IAI.70.8.3994-4001.2002

10.1073/pnas.85.12.4330

Lang T, 1994, Leishmania donovani‐infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation, J Cell Sci, 107, 2137, 10.1242/jcs.107.8.2137

10.1002/eji.1830241140

Lindsten T, 1993, Characterization of CTLA‐4 structure and expression on human T cells, J Immunol, 151, 3489, 10.4049/jimmunol.151.7.3489

10.1016/S1074-7613(94)80021-9

Murphy ML, 1998, Blockade of CTLA‐4 enhances host resistance to the intracellular pathogen, Leishmania donovani, J Immunol, 161, 4153, 10.4049/jimmunol.161.8.4153

10.1086/314520

10.1016/S0167-5699(99)01549-2

10.1016/S0065-308X(08)60208-0

10.1046/j.1365-3083.1999.00486.x

Murray HW, 1992, Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity, J Immunol, 148, 1858, 10.4049/jimmunol.148.6.1858

Kaye PM, 1991, Differential production of Th1‐ and Th2‐derived cytokines does not determine the genetically controlled or vaccine‐induced rate of cure in murine visceral leishmaniasis, J Immunol, 146, 2763, 10.4049/jimmunol.146.8.2763

10.1128/IAI.62.3.1058-1063.1994

10.1093/infdis/171.5.1309

10.1002/1521-4141(200104)31:4<1199::AID-IMMU1199>3.0.CO;2-6

10.1084/jem.167.6.1927

10.1002/(SICI)1521-4141(199802)28:02<669::AID-IMMU669>3.0.CO;2-N

Veress B, 1977, Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis, Immunology, 33, 605

10.1016/0016-5085(88)90192-8

10.1136/jcp.47.6.547

10.1046/j.1365-2613.2001.00199.x

10.1016/S0002-9440(10)64199-5

Ho M, 1983, Immunosuppression in Kenyan visceral leishmaniasis, Clin Exp Immunol, 51, 207

10.4049/jimmunol.164.4.2001

10.1128/IAI.68.11.6289-6293.2000

10.1016/S0002-9440(10)63262-2

10.1084/jem.189.4.741

10.1002/(SICI)1521-4141(199901)29:01<203::AID-IMMU203>3.0.CO;2-B

10.1128/IAI.61.4.1330-1333.1993

10.4049/jimmunol.164.7.3681

10.1128/IAI.73.11.7541-7547.2005

10.1084/jem.20040704

10.1111/j.0105-2896.2004.00188.x

Murphy ML, 1997, B7‐2 blockade enhances T cell responses to Leishmania donovani, J Immunol, 159, 4460, 10.4049/jimmunol.159.9.4460

10.1128/IAI.71.11.6453-6462.2003

10.1002/eji.200324021

Scott P, 1991, IFN‐gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis, J Immunol, 147, 3149, 10.4049/jimmunol.147.9.3149

10.1086/516482

Ghalib HW, 1995, IL‐12 enhances Th1‐type responses in human Leishmania donovani infections, J Immunol, 154, 4623, 10.4049/jimmunol.154.9.4623

Squires KE, 1989, Experimental visceral leishmaniasis: role of endogenous IFN‐gamma in host defense and tissue granulomatous response, J Immunol, 143, 4244, 10.4049/jimmunol.143.12.4244

Tumang MC, 1994, Role and effect of TNF‐alpha in experimental visceral leishmaniasis, J Immunol, 153, 768, 10.4049/jimmunol.153.2.768

10.1172/JCI117767

Murray HW, 1993, Role and effect of IL‐2 in experimental visceral leishmaniasis, J Immunol, 151, 929, 10.4049/jimmunol.151.2.929

10.1128/IAI.71.8.4804-4807.2003

10.1084/jem.185.7.1231

10.1086/515354

10.4049/jimmunol.177.1.22

10.4269/ajtmh.2006.74.1013

10.4049/jimmunol.176.9.5519

10.1006/expr.1996.0105

10.1038/ni861

Murray HW, 1987, Experimental visceral leishmaniasis: production of interleukin 2 and interferon‐gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon‐gamma, J Immunol, 138, 2290, 10.4049/jimmunol.138.7.2290

10.1038/nature01152

10.1002/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T

Wilson ME, 1998, The importance of TGF‐beta in murine visceral leishmaniasis, J Immunol, 161, 6148, 10.4049/jimmunol.161.11.6148

10.2353/ajpath.2006.050013

10.1128/IAI.70.11.6284-6293.2002

10.1086/376510

10.1172/JCI116570

10.1172/JCI116372

10.1084/jem.174.6.1549

10.1002/eji.200635937

10.1128/IAI.73.7.3903-3911.2005

10.1016/S0074-7696(08)62453-5

10.1038/nri1669

10.4049/jimmunol.176.9.5486

10.1128/IAI.72.2.824-832.2004

10.1002/eji.200535079

10.1084/jem.181.1.387

10.1128/IAI.72.1.589-592.2004

10.4049/jimmunol.176.10.6172

Kaye PM, 1987, Acquisition of cell‐mediated immunity to Leishmania. I. Primary T‐cell activation detected by IL‐2 receptor expression, Immunology, 61, 345

10.1128/IAI.50.1.169-174.1985

10.1002/1521-4141(200212)32:12<3556::AID-IMMU3556>3.0.CO;2-Q

10.1002/eji.1830271020

10.1002/eji.1830271018

10.1084/jem.20021801

10.1016/S1074-7613(00)80165-X

10.1084/jem.189.3.447

Kellermann SA, 1999, The CC chemokine receptor‐7 ligands 6Ckine and macrophage inflammatory protein‐3 beta are potent chemoattractants for in vitro‐ and in vivo‐derived dendritic cells, J Immunol, 162, 3859, 10.4049/jimmunol.162.7.3859

10.4049/jimmunol.173.8.4815

10.1128/IAI.68.4.1840-1848.2000

10.1182/blood.V95.5.1642.005k10_1642_1651

10.1128/IAI.56.5.1128-1134.1988

10.1111/j.1365-2141.1972.tb05678.x

10.1016/j.immuni.2004.10.012

10.1016/S1074-7613(03)00113-4

Ehlers S, 2003, Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF, Ann Rheum Dis, 62, ii37

10.1046/j.1365-4362.2003.01868.x

Thông tin
Thông tin xuất bản

Immunology and Cell Biology

Tập 85 Số 2

138-147

Thông tin tác giả